Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
Address
3350 RIVERWOOD PARKWAY SE, SUITE 1900
ATLANTA, GA 30339
Founded
2008
Number of Employees
8
Website
http://www.inhibikase.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)